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Abstract Objective: To test the
feasibility of applying noninvasive
ventilation (NIV) using a prototype
algorithm implemented in a bilevel
ventilation device designed to adjust
pressure support (PS) to maintain
a clinician-set alveolar ventilation in
patients with acute respiratory failure
after initial stabilization. Design
and setting: Prospective crossover
interventional study in an intensive
care unit, university hospital. Pa-
tients: 19 patients receiving NIV
for acute hypercapnic respiratory
failure (13 men, 6 women; mean
age 70 ± 11 years). Methods: The
same bilevel ventilator was used with
manually adjusted PS and with the
automated algorithm (autoPS), set to
maintain the same alveolar ventilation
as in PS. Sequence (measurements
at end of each period): (a) prior to
initiating NIV (baseline 1); (b) 45 min
with manually set PS; (c) 60 min
without NIV; (d) 45 min with autoPS;
(e) 60 min without NIV; (f) 45 min
with manually set PS. Results: The
magnitude of decrease in PaCO2
and increase in pH with autoPS was
comparable to that of conventional
PS, with the same alveolar ventila-
tion and level of PS. No technical
problem occurred in autoPS mode,
and no NIV trial had to be discon-
tinued because of patient discomfort.
Conclusions: These results suggest
that the alveolar ventilation based
automatic control of PS during NIV
with a bilevel device is feasible and
leads to beneficial effects in patients
with acute respiratory failure com-
parable to those of manually set PS.
Further studies should now explore
the potential of this system over
longer periods in patients with acute
and chronic respiratory failure.
Keywords Noninvasive ventilation ·
Pressure support · Bilevel · Auto-
mated modes
Introduction
Patient tolerance to noninvasive ventilation (NIV) is
a key element to its success in avoiding intubations in
acute respiratory failure (ARF) [1, 2]. Tolerance is highly
dependent on the combination of the patient’s spontaneous
breathing activity and the ventilator’s action, known
as patient-ventilator interaction [3]. The latter in turn
depends both on the avoidance of leaks at the mask [4,
5] and on the optimal setting of the ventilator [3, 6].
Titrating the level of pressure support (PS) is one such
challenge. Unfortunately, the large number of tasks to be
performed by the clinician in the setting of ARF carries
the risk of insufficient attention being given to adjusting
the ventilator [7].
Automation of certain ventilator settings can prove
helpful in this respect. In intubated patients the automatic
titration of PS by an expert-based knowledge system has
been shown to improve patient-ventilator interaction [8].
Whether the automatic setting of PS during NIV is
feasible remains to be seen, but it might be an attractive
option. The purpose of the present study was to test the
feasibility of relying on an automated algorithm based on
a closed-loop control of PS designed to guarantee a user-
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set minimum minute volume on a bilevel ventilator, a type
of device which, although originally designed for home
ventilation, has also been shown effective in performing
NIV in patients with ARF [9, 10]. Findings of this study
were presented in abstract form at the 2005 European




The study included 19 patients consecutively admitted to
the ICU for acute respiratory failure and in whom NIV was
prescribed (13 men, 6 women; mean age 70 ± 11 years);
all patients were hypercapnic upon inclusion (Table 1). Pa-
tients were included if they had been stabilized with NIV
after admission but had been treated in the ICU for 36 h or
longer (mean 29 ± 6 h) and had received maximally four 4
NIV applications. Exclusion criteria were a very low prob-
ability of short-term survival, a do not resuscitate order,
the presence of pneumothorax, severe respiratory failure
or hemodynamic instability with a high likelihood of im-
minent intubation, impaired consciousness or absence of
patient cooperation, and the presence of facial lesions pre-
cluding the use of NIV. Due to the technical limitations of
the bilevel device used patients requiring an FIO2 higher
than 0.6 during NIV were also excluded. The protocol was
accepted by the ethics committee of our institution. In-
formed consent was obtained from all patients.
Table 1 Patients’ clinical characteristics (BMI body mass index, PaCO2 arterial partial CO2 pressure at study inclusion, Diagnosis main
cause of acute respiratory failure, COPD chronic obstructive pulmonary disease)
Patient no. Age (years) Sex BMI PaCO2 (mmHg) Diagnosis
1 58 M 20 63 Empyema
2 76 F 23 65 Kyphoscoliosis
3 82 F 24 48 Pneumonia
4 85 M 28 66 Cardiogenic pulmonary edema
5 79 F 29 55 COPD
6 59 M 38 52 Pneumonia
7 78 M 22 47 Pneumonia
8 83 F 26 57 Cardiogenic pulmonary edema
9 72 M 24 45 Pneumonia
10 56 M 20 69 Pneumonia
11 64 M 26 74 Pneumonia
12 74 M 33 52 COPD
13 73 F 25 72 COPD
14 61 M 28 66 COPD
15 86 F 21 57 Restrictive disease
16 63 M 25 48 COPD
17 78 M 22 51 COPD
18 53 M 34 47 COPD
19 57 M 18 58 COPD
Mean ± SD 70.3 ± 10.9 – 25.4 ± 5.1 57 ± 9 –
Methods
All patients were ventilated with a new bilevel type device
(AutoVPAP, ResMed, North Ryde, Australia) allowing
two modes of bilevel PS, i.e., manually set and automatic
(autoPS). A detailed description of the rules on which
autoPS is based is beyond the scope of this contribution,
but its basic principle can be summarized as follows.
AutoPS aims to guarantee a minimum clinician-set “gross
alveolar ventilation” by adjusting the level of PS within
manually set boundaries (minimum and maximum inspi-
ratory pressures). “Gross alveolar ventilation” (termed
“alveolar ventilation” below for the sake of simplicity)
is defined to be the portion of minute volume minus
anatomical deadspace ventilation. An estimate of the
anatomical deadspace is entered by the clinician. For the
purpose of this study we used the accepted approximation
of 2.2 ml/kg body weight for deadspace [11]. The level
of PS is continuously adjusted by comparing the recent
alveolar ventilation (a continuously updated estimate
obtained by low-pass filtering, related mainly to the
ventilation during the two preceding respiratory cycles),
with the target alveolar ventilation. This means that PS
responds significantly to a change in ventilation within
about three breaths. Furthermore, a variable backup rate
is provided in the case of apnea. However, as this function
is mainly directed at patients on long-term home NIV to
deal with central apnea or an inspiratory effort too weak to
trigger the ventilator occurring during sleep, this function
was disabled in the present study, only the automatic
titration of PS being explored. Triggering is conventional,
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based on a clinician-set flow threshold. Cycling is largely
conventional, with an initial absolute refractory period
followed by a threshold based on a clinician-set proportion
of peak inspiratory flow, the default setting being 25%.
The difference between manual PS and autoPS on the
machine therefore lies in the setting of PS and determina-
tion of target alveolar ventilation as defined above, plus the
presence of a variable backup rate (which was not tested in
this study). FIO2, pressurization slope, and positive end-
expiratory pressure (PEEP) are similarly set by the clin-
ician in both modes. In both modes the maximum level
of inspiratory pressure (i.e., PS + PEEP) in this prototype
ventilator is 25 cmH2O.
Design of the study
Prior to the trial, all patients had been initially stabilized
with up to four runs of NIV applied by an oronasal
mask (adult face mask, Vygon Schweiz, Liebefeld-Bern,
Switzerland) with an ICU ventilator (Evita 4 or XL,
Drägerwerk, Lübeck, Germany). The indication for NIV
was as in our usual practice guidelines, based on published
studies [9, 12] requiring that at least two of the following
be present: worsening dyspnea over the last 10 days in
cases of chronic respiratory failure; respiratory rate greater
than 25/min; arterial pH less than 7.35; PaCO2 higher
than 50 mmHg (6.6 kPa); PaO2 below 50 mmHg (6.6 kPa),
determined from arterial blood gas measurements.
All trials with the autoVPAP device were performed
by the investigating chest physiotherapist (A. B.). NIV
was applied with an oronasal mask (UltraMirage Full Face
Mask, ResMed). For the sake of simplicity, given that
only the automatic titration of PS was tested in this study,
the term “autoPS” is used below for the phase of the trial
during which PS was titrated automatically, as opposed to
the conventional manually set mode (PS). All trials were
sequentially performed in the following order: 45 min
manually set PS (PS 1), 45 min autoPS mode (autoPS),
and 45 min manual mode (PS 2). To avoid a carry-over
effect a 60-min period without NIV was provided between
each NIV period and before PS 1. Furthermore, to avoid
any interference from the automatic backup rate function
in autoPS mode due to apnea, the patients’ level of con-
sciousness was continuously monitored during all three
NIV phases. If any signs of sleepiness or apnea appeared,
the patients were awakened and stimulated. The initial
manual settings for PS 1 and PS 2 followed our usual prac-
tice guidelines for bilevel NIV: 15 cmH2O PS, 4 cmH2O
PEEP, resulting in a PS of 11 cmH2O. Thereafter PS was
adjusted to obtain an expired tidal volume of 6–8 ml/kg
and a respiratory rate below 30/min, with a minimal leak
at the mask. In obstructive patients PEEP was titrated
upwards until the number of ineffective inspiratory at-
tempts either disappeared or decreased to less than 5/min.
Ineffective inspiratory efforts, defined as the presence of
an inspiration initiated by the patient without any response
by the ventilator, were detected by careful clinical obser-
vation. In nonobstructive patients PEEP was titrated up to
6 cmH2O to maintain pulse-oximetry determined arterial
O2 saturation (SpO2) at 90% or higher. Cycling was set at
25% and 40% of peak inspiratory flow in nonobstructive
and obstructive patients, respectively. Once the initial set-
tings were made, no further modification was performed.
The initial autoPS settings were made as follows: the
target alveolar ventilation period was set as mean minute
volume during the PS 1 period minus mean deadspace
ventilation, the latter defined as estimated anatomical
deadspace × mean respiratory rate during the PS 1 period.
The initial PS setting was identical to that set during the
PS 1, the upper and lower boundaries being 25 cmH2O (the
maximum allowed by the machine) and the level of PEEP,
respectively. Thereafter, PS was adjusted automatically to
obtain the target alveolar ventilation. Cycling, PEEP, and
pressurization slope were the same as those of PS 1.
The following measurements were taken before the
start of and at the end of each NIV period (with patients
still on NIV): arterial blood gases through an indwelling
radial artery catheter, respiratory rate, dyspnea score
(Borg visual analog scale; 0 = no dyspnea, 10 = worst pos-
sible dyspnea), expired tidal volume and minute-volume
(Fleisch no. 2 pneumotachograph, Fleisch, Lausanne,
Switzerland; between the Y-piece and the mask), heart rate
and arterial blood pressure. During NIV all ventilatory
parameters (volume, pressure, flow), leaks at the mask
(computed by the device using a mathematical model
based on the known characteristics of the mask and the
pressure and flow signals measured at the ventilator),
pulse oximetry, respiratory and heart rates, and arterial
blood pressure were continuously monitored. The reported
level of PS for periods PS 1 and PS 2 is that set once
the patient was stabilized on the machine, and for the
autoPS period it is the mean of all values automatically
set by the device during the 45 min trial. Of note, although
the autoPS algorithm targets alveolar ventilation, the
parameter that we recorded was expired minute-volume,
which is reported in the results.
Statistics
Comparisons (SigmaStat 2.0–SPSS Science) between the
six time-points were made by analysis of variance, with
statistical significance being determined by Fisher’s pro-
tected least significance test. Differences with a p-value
less than 0.05 were considered statistically significant. All
results are expressed as mean ± SD.
Results
The initial ventilator settings by the physiotherapist
led to mean PS and PEEP levels of 15.2 ± 3.5 and
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Table 2 Respiratory and hemodynamic parameters [HR heart
rate, PS level of pressure support (inspiratory pressure minus
PEEP), MAP mean systemic arterial pressure, RR respiratory rate,
VE expiratory minute-volume, VTe expired tidal volume, PaCO2
arterial partial pressure of CO2, PaO2 arterial partial pressure of
O2; baseline values measured immediately prior to initiating NIV,
PEEP positive end-expiratory pressure, PS 1 and PS 2: NIV with
manually set PS; autoPS NIV with automatic titration of PS
Baseline 1 PS 1 Baseline 2 autoPS Baseline 3 PS 2
RR (b/min) 19.2 ± 3 16.2 ± 5 18.8 ± 5 16.5 ± 4 18.8 ± 5 16 ± 5
HR (b/min) 89 ± 19 88 ± 19 92 ± 18 85 ± 16 90 ± 16 87 ± 15
MAP (mmHg) 75 ± 16 75 ± 14 80 ± 15 77 ± 13 77 ± 14 77 ± 14
Borg scale (points) 2.3 ± 1.9 1.6 ± 0.9 1.9 ± 1.6 1.7 ± 0.9 1.8 ± 1.4 1.5 ± 0.8
VE (l/min) n.a. 12.2 ± 3.1 n.a. 12.3 ± 2.8 n.a. 11.2 ± 3.3
VTe (ml) n.a. 772 ± 222 n.a. 773 ± 206 n.a. 704 ± 197
PS (cmH2O) n.a. 15.2 ± 3.4 n.a. 15.3 ± 3.1 n.a. 15.2 ± 3.4
PEEP (cmH2O) n.a. 4.9 ± 0.2 n.a. 4.8 ± 0.3 n.a. 4.8 ± 0.3
Leaks (l/min) n.a. 1.8 ± 3.5 n.a. 2.2 ± 2.8 n.a. 2.1 ± 4.4
pH 7.37 ± 0.04 7.39 ± 0.04∗ 7.37 ± 0.04 7.42 ± 0.04∗ 7.38 ± 0.04 7.43 ± 0.08
PaO2 (mmHg) 77 ± 14 75 ± 14 73 ± 14 73 ± 9 71 ± 15 72 ± 8
PaCO2 (mmHg) 57 ± 9 51 ± 10∗ 55 ± 9 49 ± 7∗ 56 ± 8 49 ± 8∗
∗p < 0.05 vs. corresponding base line (analysis of variance)
5 ± 0.5 cmH2O, respectively. The effects of NIV are
outlined in Table 2. As shown, PaCO2 and pH were com-
parably improved by both manual PS and autoPS. Individ-
ual changes in PaCO2 are shown in Fig. 1. PaO2 was un-
changed by either mode. Respiratory rate decreased from
its baseline values with both NIV modes, but the decrease
did not reach statistical significance. Dyspnea was un-
changed by either NIV mode. Expiratory minute-volume
did not differ significantly between the two NIV modes.
Overall the mean level of PS set either manually or by
autoPS were comparable, although there were differences
in some patients (Fig. 2). As seen in Fig. 3, the algorithm
Fig. 1 Individual and mean
variations in PaCO2. PS 1 and
PS 2: manually set PS; autoPS:
automatic titration of PS.∗ p < 0.05 vs. corresponding
baseline (analysis of variance)
performed little or no change in PS in some patients (e.g.,
nos. 2, 7, 17, 19), whereas more frequent and/or more
marked modifications were made in others (e.g., nos. 12,
14, 15), during the first 10 min of the autoPS trial. Leaks at
the mask were kept at a low level, and their magnitude was
comparable between manual NIV and autoPS. No apneas
or ineffective inspiratory efforts were documented during
any of the NIV trials, with either manually set ventilation
or autoPS. No change in hemodynamics occurred during
NIV (Table 2). No NIV application had to be discontinued
because of patient intolerance or technical problems. No
patient required tracheal intubation during the study.
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Fig. 2 Individual mean and
group mean values of pressure
support (PS, inspiratory pressure
minus PEEP) during each of the
three NIV periods. Values are
the mean for each 45-min trial
for each patient. PS 1 and PS 2:
manually set PS; autoPS:
automatic titration of PS
Fig. 3 Individual variation of the
level of pressure support (PS,
inspiratory pressure minus
PEEP) set by the autoPS
algorithm during the first 10 min
of NIV, as recorded by the
device; x-axis time in minutes;
y-axis level of inspiratory
pressure. In all patients the
upper limit of inspiratory
pressure (pressure support +
PEEP) was 25 cmH2O. The
lower limit, which was equal to
the PEEP level, is indicated in
each patient’s tracing (values in
cmH2O)
Discussion
The results of the present pilot study demonstrate the fea-
sibility of relying on an algorithm based on volumetric
closed-loop control to automatically adjust PS on a bilevel
device to perform NIV in patients with acute respiratory
failure, with effects comparable to those obtained by the
manual setting of PS. Before discussing the implications
of our results, several limitations should be outlined. First,
this was a feasibility study, aimed at examining whether
the concept of automatically titrating PS during NIV was
possible in patients with ARF during a 45-min period and
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how this compares to a manual setting approach. The du-
ration of NIV application was in accord with that of other
published trials [13, 14, 15]. However, any extrapolation
as to how the system would perform over longer periods
remains speculative at this time. Second, our ARF patients
had been stabilized on NIV, as reflected by low respiratory
rate and dyspnea score. Therefore whether the same results
would have been documented in more acutely decompen-
sated patients is unknown. Third, the settings in all three
NIV applications were performed by one of the investiga-
tors (A. B.), which may have biased the results. However,
safety issues mandated that an experienced therapist with
in-depth knowledge of the autoPS system supervise each
NIV application.
Fourth, as stated in the Methods section, the autoPS
algorithm is designed not only to titrate PS but also to
provide a backup rate in case of apnea. However, only PS
setting was tested in the present study, given that no apnea
occurred in our patients, as per our intention. Nonetheless
apnea can occur both in acute NIV and chronic nocturnal
home ventilation, the primary intended area of use for the
device, and the performance of the algorithm in this re-
spect remains to be evaluated, a path that we are currently
exploring. Fifth, bilevel devices have been tailored mostly
to the context of chronic long-term ventilation, and the
relevance of using such a device in the acute ICU setting
may seem questionable. However, the performance of
bilevel machines has steadily increased over the years [16,
17, 18], and these devices have been used successfully
in ARF [9, 10, 19]. Their much lower cost, relative ease
of use, and ability to function without mural medical
gas outlets makes them an attractive alternative to ICU
ventilators, especially for NIV performed outside of that
setting [20]. Finally, the number of patients was small
and consisted of a heterogeneous group. However, the
case-mix can be deemed representative of that usually
found in studies on ARF requiring NIV [21].
At this stage the results of this pilot study show that the
concept of automatically titrating PS support during NIV
with a bilevel device is feasible, a finding which opens up
possibilities in improving patient-ventilator interaction. In-
deed, caring for an ICU patient involves considerable mul-
titasking which can be a source of poor performance [22,
23]. The latter is all the more unfortunate when apply-
ing NIV since good patient ventilator synchrony, patient
comfort, and minimal mask leaks are crucial in ensuring
the success of the technique [1, 2]. In particular, exces-
sive levels of PS can worsen dynamic hyperinflation in
obstructive patients [24], in turn leading to an increase in
the number of ineffective inspiratory efforts, heighten the
incidence of gastric air intake leading to discomfort, vom-
iting and aspiration, and increase the magnitude of leaks
at the mask [25]. This being said, there is a theoretical risk
that the same excessive levels of PS could be generated
by the autoPS. Therefore one must ensure that the expired
tidal volume does not exceed 8–9 ml/kg, and also that
the inspiratory:expiratory cycling cutoff is set at a higher
level (approx. 40–50% of peak inspiratory flow) than the
usual 25% default value. This last point aims to minimize
delayed cycling, a common occurrence in patients with
chronic obstructive pulmonary disease, and one which
results in incomplete lung amptying and worsening of
dynamic hyperinflation [26]. At the other end of this
spectrum very low levels of PS can provide insufficient
respiratory muscle assistance [27]. Of note, given that
the patients had acute respiratory failure, we chose to set
the upper limit at the maximum inspiratory pressure that
the device can generate, to avoid insufficient PS. With
these settings mean expiratory minute volume was not
different during the autoPS period than in either manually
set periods.
The proof of concept that automation of PS can im-
prove patient-ventilator synchrony and comfort has been
illustrated by a study in intubated patients using an expert-
based knowledge system [8]. Extending these benefits to
NIV is in our view an attractive prospect, although perhaps
more challenging due to the presence of mask leaks and the
more unstable respiratory conditions of ARF. Nonetheless,
the results of this study, using a different ventilator and al-
gorithm, suggest that such an approach is possible, bearing
in mind that it is a pilot study.
In conclusion, these results demonstrate the feasibility
of using an algorithm to automatically adjust PS during
NIV with a bilevel device (AutoVPAP) in patients with
acute respiratory failure with beneficial effects comparable
to those of manually set PS. Further studies should now ex-
plore the potential of this approach over longer periods in
patients with acute and chronic respiratory failure.
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